Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000
- First Online:
- 84 Downloads
Since the advent of highly active antiretroviral therapy (HAART) the lengthening of AIDS incubation time has led to a decrease of AIDS incidence and mortality, and to the increase of the proportion of pre-AIDS mortality. The objective was to develop an extension of the back-calculation model by including pre-AIDS mortality and to estimate HIV prevalence in France. Our previous back-calculation model was modified to take into account the probability of survival for HIV-infected individual using the relative risk to die at different period for an HIV-infected person versus the general population (ψ). AIDS cases reported to InVS (Institut de Veille Sanitaire) until March 2003 were back-calculated to estimate HIV incidence until December 2000. AIDS deaths occurring until December 2000 were used to obtain HIV prevalence in 2000. Plausible intervals were calculated taking into account uncertainties on AIDS incubation time. Taking into account pre-AIDS mortality increased the goodness-of-fit of the model to the data. The relative risk, ψ, was estimated as 3 for homo-bisexual men, haemophiliacs and transfused cases, 10 for intravenous drug users, and 4 for heterosexual cases, with no difference over period. HIV prevalence in 2000 was estimated as 88,200 (with a plausible interval of 52,300–168,000), versus 78,200 when mortality was not considered. Pre-AIDS mortality estimates show the amount of this mortality during the era of HAART but also evidenced its existence before HAART. Taking into account pre-AIDS mortality of HIV-infected person in the back-calculation model increased the estimated HIV prevalence.
KeywordsBack-calculation method French Hospital Database on HIV HIV prevalence Pre-AIDS mortality
acquired immunodeficiency syndrome
French Hospital Database on HIV
highly active antiretroviral therapy
human immunodeficiency virus
Unable to display preview. Download preview PDF.
- 10.Bernillon P, Lièvre L, Pillonel J, Laporte A, Costagliola D. Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990–1993. The Clinical Epidemiology Group from Centres d’Information et de Soins de l’Immunodeficience Humaine Int J Epidemiol 2000;29:168–174CrossRefPubMedGoogle Scholar
- 11.Rapport Delfraissy. (2002) Prise en charge des personnes infectées par le VIH. Ministère de la Santé et de la Protection Sociale, Paris République FrançaiseGoogle Scholar
- 12.Fardet L, Mary-Krause M, Heard I, Partisani M, Costagliola D. Le sexe et le groupe de transmission de patients infectés par le VIH influencent-ils l’initiation d’un traitement anti-retroviral hautement actif et la réponse clinico-biologique sous traitement? In: 23ème réunion interdisciplinaire de chimiothérapie anti-infectieuse (RICAI); 4–5 Décembre, Paris, France; 2003; 55/10cGoogle Scholar
- 14.Lewden C. APROCO-COPILOTE Study Group, Aquitaine Cohort Study Group. Responders to antiretroviral treatment over 500 CD4/mm3 reach same mortality rates as general population: APROCO and Aquitaine cohorts, France. In: Proceedings of the 10th European AIDS Conference/EACS; Nov 17–20, 2005; Dublin, Ireland [PE18.4/8]Google Scholar
- 16.Burnham K, Anderson D. (1998) Model Selection and Inference: A Practical Information – Theoretical Approach. Springel-Verlag, New-YorkGoogle Scholar